UBAMATAMAB

UNII:	6BUL1G4D60
Type:	INGREDIENT SUBSTANCE
Formula:
Preferred Substance Name:	UBAMATAMAB
GSRS Full Record:	6BUL1G4D60 i

2305629-50-7
ANTI-MUC16/CD3 BITE ANTIBODY REGN4018
BISPECIFIC T-CELL ENGAGER ANTIBODY REGN4018
IMMUNOGLOBULIN G4 (232-PROLINE,237-PROLINE,238-VALINE,239-ALANINE,DE-240-GLYCINE,439-ARGININE,440-PHENYLALANINE,449-PROLINE), ANTI-(HUMAN CD3 ANTIGEN .EPSILON.-CHAIN) (HUMAN MONOCLONAL REGN4018 .GAMMA.4-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN4018 .KAPPA.-CHAIN, (230->223'),(233->226')-BIS(DISULFIDE) WITH IMMUNOGLOBULIN G4 (225-PROLINE,230-PROLINE,231-VALINE,232-ALANINE,DE-233-GLYCINE) ANTI-(HUMAN CANCER-ASSOCIATED ANTIGEN CA-125) (HUMAN MONOCLONAL REGN4018 .GAMMA.4-CHAIN) DISULFIDE WITH HUMAN MONOCLONAL REGN4018 .KAPPA.-CHAIN
IMMUNOGLOBULIN G4-KAPPA BISPECIFIC: ANTI-(HOMO SAPIENS T-CELL SURFACE GLYCOPROTEIN CD3 EPSILON CHAIN (T-CELL SURFACE ANTIGEN T3/LEU-4 EPSILON CHAIN, CD3E ANTIGEN)) AND ANTI-(HOMO SAPIENS MUCIN-16 (OVARIAN CANCER-RELATED TUMOR MARKER CA125, OVARIAN CARCINOMA ANTIGEN CA125)); HUMAN MONOCLONAL ANTIBODY; .GAMMA.4 HEAVY CHAIN ANTI CD3 ANTIGEN(1-450) (HOMO SAPIENS VH (IGHV3-9*01 (98%) (IGHD)-IGHJ1*01 (91%)) (8.8.17) (1-124)-HOMO SAPIENS IGHG4*01 (HINGE(S10>P(232)), CH2(E3>P(237),F4>V(238), L5>DEL,G6>A(239)), CH3(H95>R(438),Y96>F(439),L105>P(448))) (125-450)) (138-215')-DISULFIDE WITH .KAPPA. LIGHT CHAIN (1'-215') (HOMO SAPIENS V-KAPPA (HOMO SAPIENS IGKV1-39*01 (98%) IGKJ5*01)(6.3.10) (1'-108')-HOMO SAPIENS IGKC*01 (109'-215')); (230-223'':233-226'')-BISDISULFIDE WITH .GAMMA.4 HEAVY CHAIN ANTI CA125 ANTIGEN(1''-443'') (HOMO SAPIENS VH (IGHV3-11*01 (89%) (IGHD)-IGHJ5*01) (8.8.10) (1''-117'')-HOMO SAPIENS IGHG4*01 (HINGE(S10>P(225'')), CH2(E3>P(230''), F4>V(231''),L5>DEL,G6>A(232''))) (118''-443'')) (131''-215''')-DISULFIDE WITH .KAPPA. LIGHT CHAIN (1'''-215''') (HOMO SAPIENS V-KAPPA (HOMO SAPIENS IGKV1-39*01 (98%) IGKJ5*01)(6.3.10) (1'''-108''')-HOMO SAPIENS IGKC*01 (109'''-215'''))
MUC16XCD3 BISPECIFIC T-CELL ENGAGER REGN4018
REGN-4018
REGN4018
UBAMATAMAB [USAN]
Ubamatamab [WHO-DD]
ubamatamab [INN]

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

UBAMATAMAB

Synonyms and Mappings

Resources